The FDA has received 8,571 reports of gastrointestinal disorders after use of semaglutide medications, which includes both Ozempic and Wegovy, according to data published by the regulator through ...

The injectable drug Ozempic is shown Saturday, July 1, 2023, in Houston. (AP Photo/David J. Phillip) ... 503A and 503B, based on the FDA regulations that govern their operations.

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

If you're following the GLP-1 (Ozempic and other prescription weight-loss medications) scene, you may have read that the FDA set a cut-off date for this month on pharmacies that compound GLP-1 ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now that the GLP-1 drug shortage has ended. People who rely on compounded GLP ...

OMAHA, Neb. (WOWT) - The FDA is cracking down on off brand weight loss products similar to Ozempic. GLP-1 drugs for weight loss like Wegovy or Zepbound were previously in a shortage.

On February 21, 2025, the FDA updated its drug shortage list and labeled the shortage of all doses of injectable semaglutide (Ozempic/Wegovy) as being resolved. The FDA’s announcement will ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

ROCKVILLE, MD – The Obesity Society (TOS) acknowledges the U.S. Food and Drug Administration's (FDA) recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and Ozempic; two ...

According to the FDA, semaglutide, the class of drugs like Ozempic, and tirzepatide, the class of drugs like Mounjaro, are no longer in short supply, therefore prohibiting compounding.